A TCR-Like CAR Recruiting Endogenous CD3 Proves Efficacious Tumor Antigen Recognition via Retroviral, IVT-RNA or CRISPR/Cas9 Expression Systems in Human T-Cells and Perceives Costimulatory Signals in Cis

被引:0
|
作者
Voss, Ralf-Holger [1 ]
Birtel, Matthias [2 ,3 ]
Theobald, Matthias [4 ,5 ]
Oehm, Petra [2 ]
Sahin, Ugur [1 ,2 ,3 ]
机构
[1] Univ Med Ctr UMC, Res Ctr Immunotherapy FZI, Mainz, Germany
[2] BioNTech AG, Mainz, Germany
[3] TRON Translat Oncol gGmbH, Mainz, Germany
[4] Univ Med Ctr UMC, Dept Hematol Oncol & Pneumol, Mainz, Germany
[5] Univ Canc Ctr UCT, Mainz, Germany
关键词
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
681
引用
收藏
页码:329 / 330
页数:2
相关论文
共 1 条
  • [1] A combinatory CAR relying on T-cell signaling via endogenous CD3 elicits paramount tumor antigen sensitivity via retrovirally, ivt-RNA-, or CRISPR/Cas9 NHEJ/HDR-treated human T-cells
    Voss, R. H.
    Birtel, M.
    Oehm, P.
    Theobald, M.
    Sahin, U.
    HUMAN GENE THERAPY, 2019, 30 (11) : A71 - A71